The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It plans to deliver over 300 million doses to the Indian government
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company has developed the API in house at its R&D center in Hyderabad
Zeebon is the largest diagnostics services provider in North-Eastern states
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
The product is expected to be available in a week’s time
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Subscribe To Our Newsletter & Stay Updated
